Physician profile
Kaleem Gill
NPI 1629012117
$3,865.14
in general payments reported to CMS, 2019-2025
31 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,339 · 2020: $794 · 2021: $887 · 2022: $359 · 2023: $100 · 2024: $282 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $576.59 | 2021-2025 | |
| Pfizer INC. | $571.96 | 2019-2024 | |
| Novo Nordisk INC | $426.44 | 2019-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $232.45 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $187.95 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.88 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $185.83 | 2019-2020 | |
| Lilly USA, LLC | $167.30 | 2019-2024 | Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $124.86 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $123.44 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $101.95 | 2020-2021 | |
| Amarin Pharma, INC. | $98.08 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $86.60 | 2020-2022 | |
| Amgen INC. | $73.07 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $65.61 | 2019-2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $62.41 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.99 | 2022-2023 | |
| Allergan, INC. | $42.01 | 2019-2020 | |
| Glaxosmithkline, LLC. | $38.35 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $32.86 | 2019 | |
| Eisai INC. | $27.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.88 | 2019-2021 | |
| Vivus LLC | $22.67 | 2020 | |
| Scilex Pharmaceuticals INC. | $21.18 | 2019 | |
| Dexcom, INC. | $19.99 | 2023 | Dexcom G6 Transmitter |
| Advanced Respiratory, INC | $16.84 | 2020 | |
| Corium, LLC | $14.40 | 2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $13.11 | 2019 | |
| Mannkind Corporation | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaleem Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.